Anaplastic thyroid carcinoma (ATC) has a rapidly fatal
clinical course, being resistant to
multimodal treatments. Microtubules, α/β
tubulin heterodimers, are crucial in cell signaling, division and mitosis and are among the most successful targets for anticancer
therapy.
Panobinostat (
LBH589) is a potent deacetylase inhibitor acting both on
histones and nonhistonic
proteins, including α-
tubulin. In vitro
LBH589, evaluated in three ATC cell lines (
BHT-101, CAL-62 and 8305C), resulted in impairment of cell viability, inhibition of colony formation, cell cycle arrest and apoptosis induction. Mechanistically, we showed that
LBH589 not only affected the expression of p21 and
cyclin D1, but markedly determined microtubule stabilization as evidenced by
tubulin acetylation and increased
tubulin polymerization. In a SCID xenograft model implanted with CAL-62 cells, the cytotoxic properties of
LBH589 were confirmed. The
drug at the dose of 20 mg/kg significantly impaired
tumor growth (final
tumor volume 2.5-fold smaller than in untreated animals); at this dose, no relevant side effects were observed. In
tumors of treated animals, a significant reduction of Ki67, which was negatively correlated with
tubulin acetylation, was observed. Moreover, acetyl-
tubulin levels negatively correlated with
tumor volume at sacrifice, reinforcing the opinion that
tubulin acetylation has a role in the inhibition of
tumor growth. In conclusion,
LBH589, acting on both
histones and nonhistonic
proteins in
anaplastic thyroid cancer, appears to be a promising therapeutic agent for the treatment of this kind of
cancer which is known not to respond to conventional
therapy.